AtaiBeckley To Participate in Upcoming Investor Conferences
Rhea-AI Summary
AtaiBeckley (NASDAQ: ATAI) said its CEO Srinivas Rao, M.D., Ph.D., and VP of Investor Relations Jason Awe, Ph.D., will attend investor conferences in March 2026 with fireside chats and one-on-one meetings.
Events: TD Cowen (Boston) on March 4 with a fireside chat 11:50am–12:20pm EST; Jefferies Biotech on March 10 (one-on-ones) in Miami; Leerink (Miami) on March 11 with a fireside chat 8:00am–8:30am EST. Live webcasts of the fireside chats will be available on the company's investor site and archived for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ATAI
In the Feb 17 session, ATAI gained 6.44%, reflecting a notable positive market reaction. Argus tracked a peak move of +11.3% during that session. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following investor conferences in March.
TD Cowen 46th Annual Health Care Conference
- Format: Fireside chat, Wednesday, March 4, from 11:50am – 12:20pm EST and one-on-one meetings
- Location: Boston, Massachusetts
Jefferies 2026 Biotech on the Beach
- Format: One-on-one meetings only, Tuesday, March 10
- Location: Miami, Florida
Leerink Global Healthcare Conference
- Format: Fireside chat, Wednesday, March 11, from 8:00am – 8:30am EST and one-on-one meetings
- Location: Miami, Florida
Live webcasts of the fireside chats will be available on the investor section of the AtaiBeckley website, under Events. The archived webcasts will be available for at least 30 days after the event.
About AtaiBeckley Inc.
AtaiBeckley is a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder. BPL-003 is in Phase 3 planning, VLS-01 and EMP-01 are in Phase 2 clinical development. The Company is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create breakthroughs in mental health through transformative interventional psychiatry therapies that can integrate seamlessly into healthcare systems.
For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.
Investor and Media Relations
Investors:
Jason Awe, PhD
VP, Investor Relations
IR@ataibeckley.com
Media:
Charlotte Chorley
Associate Director, Communications
PR@ataibeckley.com
